ELSEVIER

Contents lists available at ScienceDirect

Biochemical Pharmacology

journal homepage: www.elsevier.com/locate/biochempharm



Corrigendum

Corrigendum to "Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas" [Biochem. Pharmacol. 81 (2011) 1106–1115]

Naoki Mori ^{a,*}, Chie Ishikawa ^{a,b}, Masachika Senba ^c, Masashi Kimura ^d, Yukio Okano ^d

The authors regret that in Materials and methods in the above article, the following description in section 2.4. *Immunohistochemical analysis* is incorrect: The study was approved by the Ethics Committee of University of the Ryukyus. The correct description is: The study was approved by the Ethics Committee of Nagasaki Tissue Registry.

a Department of Microbiology and Oncology, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan

b Transdisciplinary Research Organization for Subtropics and Island Studies, University of the Ryukyus, 1 Senbaru, Nishihara, Okinawa 903-0213, Japan

^c Department of Pathology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan

^d Department of Molecular Pathobiochemistry, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan

DOI of original article: 10.1016/j.bcp.2011.02.010

^{*} Corresponding author. Current address: Department of Internal Medicine, Omoromachi Medical Center, 1-3-1 Uenoya, Naha, Okinawa 900-0011, Japan. Tel.: +81 98 867 2116; fax: +81 98 861 2398.